{"schema_version":"secwatch.filing_event.v1","accession":"0001411690-25-000082","form_type":"8-K","ticker":"BNGO","cik":"0001411690","company_name":"Bionano Genomics, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.923542+00:00","generated_at":"2026-05-17T13:01:12.055724+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"medium","headline":"Bionano Q2 2025 revenue $6.7M (-13% YoY); gross margin 52% vs 33%; flowcell sales +17%","bullets":["Total revenue $6.7M (-13% YoY); prior year included $0.7M discontinued clinical services; adjusted consumables/software/services up 11%.","Gross margin 52% (non-GAAP 52%) vs 33% a year ago; operating expenses cut 42% to $11.3M.","Sold 7,233 flowcells (+17% YoY); installed OGM base 378 systems (+4% YoY).","Full-year 2025 revenue reaffirmed $26-30M; Q3 2025 guidance $6.7-7.2M; cash runway into Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001411690-25-000082","json":"https://secwatch.observer/filing/0001411690-25-000082.json","markdown":"https://secwatch.observer/filing/0001411690-25-000082.md","text":"https://secwatch.observer/filing/0001411690-25-000082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411690/000141169025000082/0001411690-25-000082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411690/000141169025000082/bngo-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:01:12.055724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}